MedTrace Logo

Protocol to Distinguish Tumor Recurrence From Treatment-Related Necrosis in Patients With High Grade Gliomas

NCT00942760 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2013-05-08

No results posted yet for this study

Summary

Brain imaging tests are routinely used to detect the presence of a brain tumor or to evaluate the response to treatment. Sometimes the images obtained are not specific and the only way to establish a diagnosis is by obtaining a tissue sample. The hypotheses of the study is to determine if multimodal MR technique will provide tissue signatures that differentiate between tumor progression and treatment related necrosis in high grade glioma patients.

Conditions

  • Recurrent High Grade Gliomas

Interventions

DEVICE

3T MRI

The introduction of the 3T scanners provides a potential opportunity to improve the quality of imaging in neuro-oncology.

Sponsors & Collaborators

  • Dartmouth-Hitchcock Medical Center

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2011-03-31
Completion
2011-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00942760 on ClinicalTrials.gov